LENZ Therapeutics, Inc.
LENZ
$38.79
-$0.89-2.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.00M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.00M | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 5.00M | -- | -- | -- | -- |
| SG&A Expenses | 39.76M | 34.37M | 28.81M | 24.91M | 21.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.96M | 59.45M | 58.61M | 68.37M | 75.29M |
| Operating Income | -61.96M | -59.45M | -58.61M | -68.37M | -75.29M |
| Income Before Tax | -51.90M | -47.74M | -49.77M | -60.99M | -69.65M |
| Income Tax Expenses | 501.00K | 1.00K | 1.00K | -179.00K | -179.00K |
| Earnings from Continuing Operations | -52.40 | -47.74 | -49.77 | -60.81 | -69.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.40M | -47.74M | -49.77M | -60.81M | -69.47M |
| EBIT | -61.96M | -59.45M | -58.61M | -68.37M | -75.29M |
| EBITDA | -61.87M | -59.36M | -58.55M | -68.34M | -75.26M |
| EPS Basic | -1.90 | -1.77 | -4.77 | -16.35 | -25.59 |
| Normalized Basic EPS | -1.18 | -1.14 | -3.01 | -10.31 | -16.09 |
| EPS Diluted | -1.90 | -1.77 | -4.77 | -16.35 | -25.59 |
| Normalized Diluted EPS | -1.18 | -1.14 | -3.01 | -10.31 | -16.09 |
| Average Basic Shares Outstanding | 110.27M | 107.80M | 84.99M | 59.47M | 34.26M |
| Average Diluted Shares Outstanding | 110.27M | 107.80M | 84.99M | 59.47M | 34.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |